Oppenheimer lowered the firm’s price target on Zura Bio to $16 from $17 and keeps an Outperform rating on the shares. The firm notes that on Thursday, Zura announced full-year 2023 results, along with the news that founding CEO Someit Sidhu will be turning over the reins to current president Robert Lisicki. Oppenheimer views this as a post-deSPAC adjustment, with other updates including continued fine-tuning of the clinical development plans for Zura’s portfolio of clinical stage assets.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZURA:
- Zura Bio Announces Leadership Change as New CEO Steps In
- Zura Bio names Robert Lisicki as CEO, succeeding Someit Sidhu, M.D.
- Zura Bio Outlines Corporate Strategy and Financial Projections
- Zura Bio Releases Informative Update for Investors
- Piper Sandler healthcare analysts to hold an analyst/industry conference call